Aileron Therapeutics (NASDAQ:ALRN) PT Raised to $19.00

Aileron Therapeutics (NASDAQ:ALRN) had its price target lifted by equities researchers at LADENBURG THALM/SH SH from $9.00 to $19.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price objective indicates a potential upside of 347.06% from the stock’s current price.

Aileron Therapeutics Stock Down 20.6 %

Shares of NASDAQ ALRN opened at $4.25 on Thursday. The firm has a market capitalization of $20.78 million, a P/E ratio of -1.26 and a beta of 2.22. The stock’s 50-day simple moving average is $5.39 and its two-hundred day simple moving average is $3.59. Aileron Therapeutics has a twelve month low of $1.01 and a twelve month high of $7.12.

Hedge Funds Weigh In On Aileron Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in shares of Aileron Therapeutics by 65.5% during the 3rd quarter. Renaissance Technologies LLC now owns 190,691 shares of the company’s stock valued at $39,000 after purchasing an additional 75,500 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Aileron Therapeutics by 52.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock valued at $38,000 after purchasing an additional 63,651 shares during the last quarter. Sigma Planning Corp bought a new position in shares of Aileron Therapeutics during the 4th quarter valued at about $51,000. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Aileron Therapeutics during the 4th quarter valued at about $48,000. Finally, Geode Capital Management LLC increased its position in shares of Aileron Therapeutics by 23.2% during the 1st quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock valued at $68,000 after purchasing an additional 10,311 shares during the last quarter. 90.89% of the stock is currently owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.